News

Gilead Research and Development executive vice president and chief scientific officer Norbert Bischofberger said: “Direct-acting antiviral treatments have transformed our ability to treat hepatitis C; however, for some

As part of the settlement and license agreement, all claims in the relevant legal proceedings will be dismissed, and the companies have granted certain patent rights to each

This multicenter trial is designed to assess the feasibility, safety and exploratory efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy.

The company specializes in the field of opioid addiction, emergency care and sterile injectables. By joining forces with Martindale Pharma, Ethypharm reinforces its presence in the UK. The

Abeona Therapeutics president & CEO Timothy Miller said: “This designation builds on our commercial portfolio of AAV gene therapies that have received FDA and EMA orphan drug designations, which is an

In addition, the FDA removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials. John Mendlein, PhD, CEO of aTyr Pharma, said: "This Fast

The Ireland based pharma maintained that it did not admit to any wrongdoing in the acquisition deal of synthetic ACTH product Synacthen Depot by Questcor Pharmaceuticals from Novartis

TAK-935 has successfully completed several Phase 1 clinical studies under Takeda’s leadership and will be moving into Phase 1b/2a clinical studies in rare epileptic encephalopathies where patients continue

Boehringer Ingelheim Therapeutic Area Biosimilars senior vice president and head Ivan Blanarik said: “We believe that if approved, BI 695501 can provide a valuable treatment option for the